Quantum-Si (NASDAQ:QSI – Get Free Report) and Cytek Biosciences (NASDAQ:CTKB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Insider and Institutional Ownership
39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Quantum-Si and Cytek Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum-Si | $2.44 million | 68.73 | -$101.34 million | ($0.46) | -1.67 |
| Cytek Biosciences | $201.49 million | 3.03 | -$66.54 million | ($0.62) | -7.58 |
Cytek Biosciences has higher revenue and earnings than Quantum-Si. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Quantum-Si has a beta of 3.24, meaning that its stock price is 224% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Profitability
This table compares Quantum-Si and Cytek Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
| Cytek Biosciences | -38.98% | -12.40% | -9.17% |
Analyst Recommendations
This is a breakdown of recent ratings for Quantum-Si and Cytek Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
| Cytek Biosciences | 1 | 2 | 3 | 0 | 2.33 |
Quantum-Si currently has a consensus price target of $1.00, indicating a potential upside of 29.85%. Cytek Biosciences has a consensus price target of $5.56, indicating a potential upside of 18.35%. Given Quantum-Si’s higher possible upside, analysts plainly believe Quantum-Si is more favorable than Cytek Biosciences.
Summary
Cytek Biosciences beats Quantum-Si on 8 of the 14 factors compared between the two stocks.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
About Cytek Biosciences
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
